Phase 3 N=168 Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
Hypertension, · Hyperlipidemia
Primary: sitDBP Changes at Week 8 From Baseline — -9.24; -2.9 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=126 Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index — 66 percentage of subjects responding
Phase 3 N=110 Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions — 4; 5 participants
Phase 3 N=619 Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85 — -0.030; 0.092; 0.081 Liters — p=<0.001
Phase 3 N=36 Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age
Sedation
Primary: Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion — 7.1; 7.1; 25 percentage of subjects
Phase 3 N=71 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
Hemophilia A
Primary: Occurrence of FVIII Inhibitor Development — 0; 0; 0; 0 percentage of participants
Phase 3 N=16 A Study Investigating Treatment Factor X in People With Factor X Deficiency
Factor X Deficiency
Primary: FX:C Incremental Recovery — 2.07 IU/dL per IU/kg
Phase 3 N=15 A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder
General Anxiety Disorder, Social Anxiety Disorder
Primary: Hamilton Anxiety Scale — 10.9 units on a scale
Phase 3 N=441 A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
Hyperphosphatemia · Kidney Failure
Primary: Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56) — 5.44; 5.12; 7.23; 4.89 mg/dL — p=<0.0001
Phase 3 N=38 Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities
PTSD
Primary: Clinician Administered PTSD Scale (CAPS) — -21.72 Change in units on a scale
Phase 3 N=661 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Rabies · Japanese Encephalitis
Primary: Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination — 100; 100 Percentages of subjects
Phase 3 N=647 [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
Hypertriglyceridemia · Cardiovascular Disease
Primary: Serum Non-HDL Cholesterol — -3.86; -6.91; -0.91 Percent change from baseline — p=<0.05
Phase 3 N=1,316 Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Infant, Newborn, Diseases · Other Preterm Infants · Infant, Small for Gestational Age
Primary: Survival Without Bronchopulmonary Dysplasia (BPD) — 346; 320 Participants
Phase 3 N=905 Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain
Chronic Low Back Pain
Primary: Mean Pain Intensity for "Average Pain Over the Last 24 Hours" Score — 3.7; 4.2 units on a scale
Phase 3 N=922 Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
Chronic Nonmalignant and Nonneuropathic Pain
Primary: The Number of Participants With Adverse Events as a Measure of Safety — 80; 6; 586; 0 participants